CPC A61K 31/506 (2013.01) [A61K 31/203 (2013.01); A61K 31/4375 (2013.01); A61K 31/44 (2013.01); A61K 31/496 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/706 (2013.01); A61P 35/00 (2018.01)] | 20 Claims |
1. A method for treating an acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or melanoma comprising administering to a subject in need thereof a compound selected from:
or a pharmaceutically acceptable salt thereof,
and one or more additional therapeutic agent selected from a PI3K inhibitor, a MTOR inhibitor, an AKT inhibitor, a BRAF inhibitor, a MEK1 inhibitor, a MEK2 inhibitor, an ERK inhibitor, an EGFR inhibitor, a DNMT inhibitor, a cKIT inhibitor, and a CDK4/6 inhibitor, or any combination thereof.
|